Drug Profile
KHK 2455
Alternative Names: KHK2455Latest Information Update: 24 Jan 2023
Price :
$50
*
At a glance
- Originator Kyowa Kirin Pharmaceutical Development
- Class Antineoplastics; Small molecules
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Glioblastoma
- Discontinued Solid tumours; Urogenital cancer
Most Recent Events
- 18 Jan 2023 Kyowa Kirin terminates a phase I trial in Urogenital cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Spain (PO) based on the business decision (NCT03915405)
- 17 Aug 2022 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (PO)
- 17 Aug 2022 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)